IFRXのチャート
IFRXの企業情報
| symbol | IFRx |
|---|---|
| 会社名 | InflaRx NV （インフラRx） |
| 分野（sector） | ― |
| 産業（industry） | ― |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Inflarx NV formerly Fireman BV is a holding company for InflaRx GmbH a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate IFX-1 is an intravenously delivered first-in-class anti-C5a monoclonal antibody undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS) a rare and chronic debilitating systemic inflammatory skin disease and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2 which is in preclinical development. インフラRxはドイツのバイオ医薬品企業。米国において、C5a技術を使用し阻害剤の発見・開発に従事する。同社のC5a技術は自己免疫疾患や炎症性疾患の治療のために開発され、腹水炎の予防のために静脈内に送達された抗C5aモノクロ―ナル抗体IFX-1の開発に関与している。また、ANCA関連血管炎の治療にIFX-2が開発される。 inflarx n.v., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using c5a technology primarily in the germany and united states. its c5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. the company's lead product candidate is ifx-1, an intravenously delivered first-in-class anti-c5a monoclonal antibody, which completed the phase iib clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat anca-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing ifx-1 for the treatment of oncological diseases. it also develops ifx-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. inflarx n.v. has co-development agreement with beijing defe |
| 本社所在地 | Winzerlaer Strasse 2 Jena 07745 DEU |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +49 3641-50-8180 |
| 設立年月日 | 42887 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | 21人 |
| url | www.inflarx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ifrx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -33.47187 |
| 終値（lastsale） | 34.3 |
| 時価総額（marketcap） | 880210030 |
| 時価総額 | 時価総額（百万ドル） 839.85550 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 660.17260 |
| 当期純利益 | 当期純利益（百万ドル） -32.84556 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Inflarx NV revenues was not reported. Net loss increased 51% to EUR12.8M. Higher net loss reflects Research and development expenses increase of 91% to EUR10.5M (expense) General and administrative expenses increase from EUR1.3M to EUR6.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -EUR0.36 to -EUR0.51. |
IFRXのテクニカル分析
IFRXのニュース
FDA Grants Emergency Use Authorization for InflaRx COVID-19 Drug in Critically Ill Patients 2023/04/05 14:52:54 The Epoch Times
Biopharmaceutical company InflaRx NV’s monoclonal antibody has been granted emergency use authorization (EUA) by the Food and Drug Administration (FDA) for the treatment of COVID-19 in hospitalized adults. The FDA said on April 4 that it had issued the EUA for the use of Gohibic, a brand name of vilobelimab, a monoclonal anti-human complement factor C5a antibody, to be injected into hospitalized […]
InflaRx (NASDAQ:IFRX) Stock Spikes: Is There Further Upside? 2023/04/05 10:05:03 TipRanks
Shares of InflaRx (NASDAQ:IFRX) jumped 83.9% on Tuesday, April 4. Further, its stock is up about 11.4% in the pre-market session on Wednesday. Whil…
US stock market closes with a decline, Dow Jones drops by 0.59% 2023/04/05 02:30:00 InstaForex
The number of job vacancies in the US in February fell to its lowest level in almost two years, indicating a cooling labor market, while manufacturing orders fell for the second consecutive month. After the publication of this data, stocks began to fluctuate. Investors were waiting for this statistics to assess the resilience of the economy and get hints about the future increase in interest rates after the recent banking crisis. At the close of the New York Stock Exchange, the Dow Jones index fell by 0.59%, the S&P 500 index dropped by 0.58%, and the NASDAQ Composite index fell by 0.52%. Among the growth leaders of the components of the Dow Jones index at the end of today''s trading were shares of Nike Inc (NYSE:NKE), which appreciated by 2.02 points (1.66%), closing at 123.69. Amgen Inc (NASDAQ:AMGN) quotes increased by 3.09 points (1.26%), finishing trading at 247.53. Walgreens Boots Alliance Inc (NASDAQ:WBA) shares rose in price by 0.39 points (1.10%), closing at 35.85. The leaders in decline were shares of Caterpillar Inc (NYSE:CAT), the price of which fell by 12.42 points (5.40%), closing the session at 217.45.
Inflarx NV PT Lowered to $6 at H.C. Wainwright 2023/01/06 12:00:02 Investing.com
https://www.investing.com/news/pro/inflarx-nv-pt-lowered-to-6-at-hc-wainwright-432SI-2974619
InflaRx Soar after Amending COVID-19 Treatment Agreement 2022/12/21 18:22:49 TipRanks
Shares of InflaRx (NASDAQ:IFRX) are surging higher today, which can be attributed to the company amending its agreement with Staidson BioPharmaceut…
Inflarx NV PT Lowered to $6 at H.C. Wainwright 2023/01/06 12:00:02 Investing.com
https://www.investing.com/news/pro/inflarx-nv-pt-lowered-to-6-at-hc-wainwright-432SI-2974619
InflaRx Soar after Amending COVID-19 Treatment Agreement 2022/12/21 18:22:49 TipRanks
Shares of InflaRx (NASDAQ:IFRX) are surging higher today, which can be attributed to the company amending its agreement with Staidson BioPharmaceut…
Inflarx NV PT Raised to $8 at Raymond James 2022/11/10 12:05:13 Investing.com
https://www.investing.com/news/pro/inflarx-nv-pt-raised-to-8-at-raymond-james-432SI-2939730
Inflarx NV PT Raised to $8 at H.C. Wainwright 2022/08/08 10:52:04 Investing.com
https://www.investing.com/news/pro/inflarx-nv-pt-raised-to-8-at-hc-wainwright-432SI-2866505
If You’re Considering Buying InflaRx N.V. (NASDAQ: IFRX) Stock, Read This First. 2022/06/18 12:00:00 Stocks Register
InflaRx N.V. (NASDAQ:IFRX) price on Friday, June 17, fall -3.20% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.21. A look at the stock’s price movement, the close in the last trading session was $1.25, moving within a range at $1.12 and $1.31. The beta value (5-Year … If You’re Considering Buying InflaRx N.V. (NASDAQ: IFRX) Stock, Read This First. Read More »
Inflarx NV PT Raised to $8 at Raymond James 2022/11/10 12:05:13 Investing.com
https://www.investing.com/news/pro/inflarx-nv-pt-raised-to-8-at-raymond-james-432SI-2939730
Inflarx NV PT Raised to $8 at H.C. Wainwright 2022/08/08 10:52:04 Investing.com
https://www.investing.com/news/pro/inflarx-nv-pt-raised-to-8-at-hc-wainwright-432SI-2866505
If You’re Considering Buying InflaRx N.V. (NASDAQ: IFRX) Stock, Read This First. 2022/06/18 12:00:00 Stocks Register
InflaRx N.V. (NASDAQ:IFRX) price on Friday, June 17, fall -3.20% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.21. A look at the stock’s price movement, the close in the last trading session was $1.25, moving within a range at $1.12 and $1.31. The beta value (5-Year … If You’re Considering Buying InflaRx N.V. (NASDAQ: IFRX) Stock, Read This First. Read More »
InflaRx (IFRX) presents at H.C. Wainwright Global Investment Conference - Slideshow (NASDAQ:IFRX) 2022/05/24 18:59:36 Seeking Alpha
The following slide deck was published by InflaRx N.V.
Read Why Did Raymond James Slash Price Target On Inflarx 2022/05/13 17:55:11 Benzinga
Raymond James remains a Strong Buy on Inflarx NV (NASDAQ: IFRX ) following 1Q22 earnings based on a promising outlook for vilobelimab in Pyoderma Gangrenosum (PG) and potentially other indications. The biotech macro backdrop has forced many companies to be prudent with cash runway and prioritize clinical programs. InflaRx is also focusing on a potential pivotal trial in PG, halting (for now) hidradenitis suppurativa (HS) and ANCA … Full story available on Benzinga.com